New publication on the journal Microorganisms by Luca Spaggiari, Natalia Pedretti, Muhammad Behzad, Ramona Iseppi, Carla Sabia, Maria Teresa Franzè, Carolina Cason, Rosario Russo, Manola Comar, Francesco De Seta, Andrea Ardizzoni and Eva Pericolini. The article “Prophylactic potential of Heyndrickxia coagulans strain LMG S-24828 in an in vitro model of ESBL–Escherichia coli urothelial infection” is the result of the collaboration between the MicroModenaLab group, the company Giellepi S.p.A (Seregno, Italy), the University of Trieste, and the University Vita and Salute, San Raffaele Scientific Institute, Milan.
ABSTRACT
Urinary tract infections (UTIs) are among the most common bacterial infections and represent a significant health concern worldwide. The most common cause of these infections is the Gram-negative bacterium Escherichia coli (E. coli), an opportunistic commensal of the human gut that can shift to pathogenicity, leading to a wide variety of diseases. The increasing ability of E. coli to develop resistance to various classes of antibiotics underscores the urgent need for alternative approaches to clear up infections caused by this species. In this study, we analyzed the possible beneficial role of Heyndrickxia coagulans (H. coagulans) strain LMG S-24828 in an in vitro model of T24 urothelial cells infection by ESBL-producing E. coli. Our results showed that H. coagulans LMG S-24828 was able to: (i) reduce E. coli growth; (ii) impair E. coli adhesion to T24 urothelial cells; and (iii) modulate cytokine production by T24 urothelial cells per se and after E. coli infection. Collectively, these findings indicate a beneficial effect of H. coagulans strain LMG S-24828 against an ESBL–E. coli isolate in an in vitro model of T24 urothelial cell infection.
See the full text at: https://www.mdpi.com/2076-2607/14/3/606